Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.23 USD | +6.95% | +7.67% | +0.31% |
02:29pm | Earnings Flash (OVID) OVID THERAPEUTICS Posts Q1 Revenue $148,000 | MT |
Apr. 30 | B. Riley Securities Initiates Ovid Therapeutics With Buy Rating, $9 Price Target | MT |
Financials (USD)
Sales 2024 * | 11.42M | Sales 2025 * | 43.7M | Capitalization | 214M |
---|---|---|---|---|---|
Net income 2024 * | -55M | Net income 2025 * | -31M | EV / Sales 2024 * | 18.7 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 4.89 x |
P/E ratio 2024 * |
-3.97
x | P/E ratio 2025 * |
-7.89
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.1% |
Latest transcript on Ovid Therapeutics Inc.
1 day | +0.17% | ||
1 week | +0.83% | ||
Current month | -0.82% | ||
1 month | -5.47% | ||
3 months | -19.76% | ||
6 months | -14.06% | ||
Current year | -6.06% |
Managers | Title | Age | Since |
---|---|---|---|
Jeremy Levin
CEO | Chief Executive Officer | 70 | 14-03-31 |
Jeffrey Rona
DFI | Director of Finance/CFO | 55 | 18-12-31 |
Zhong Zhong
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Barbara Duncan
BRD | Director/Board Member | 59 | 17-06-13 |
Bart Friedman
BRD | Director/Board Member | 79 | 15-11-22 |
Jeremy Levin
CEO | Chief Executive Officer | 70 | 14-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +3.48% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 3.23 | +6.95% | 122 716 |
24-05-13 | 3.02 | +0.67% | 69,595 |
24-05-10 | 3 | -1.64% | 54,455 |
24-05-09 | 3.05 | -1.29% | 99,248 |
24-05-08 | 3.09 | +3.00% | 99,242 |
Delayed Quote Nasdaq, May 14, 2024 at 09:46 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.06% | 214M | |
+4.90% | 111B | |
+10.85% | 105B | |
-12.27% | 22.34B | |
-3.03% | 21.93B | |
-5.80% | 18.59B | |
-36.52% | 18.12B | |
-9.51% | 16.96B | |
+3.66% | 13.7B | |
+36.98% | 12.45B |
- Stock Market
- Equities
- OVID Stock